Skip to main content
Erschienen in: Angiogenesis 4/2013

01.10.2013 | Original Paper

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

verfasst von: Purnachandra Nagaraju Ganji, Wungki Park, Jing Wen, Hemchandra Mahaseth, Jerome Landry, Alton B. Farris, Field Willingham, Patrick S. Sullivan, David A. Proia, Iman El-Hariry, LaTonia Taliaferro-Smith, Roberto Diaz, Bassel F. El-Rayes

Erschienen in: Angiogenesis | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Hypoxia-inducible factors (HIFs) and STAT-3 play essential roles in angiogenesis. HIF-1α and STAT-3 are clients of the heat shock protein 90 (HSP90). We hypothesized that ganetespib, a potent HSP90 inhibitor, would disrupt angiogenesis in colorectal cancer (CRC) through inhibition of HIF-1α and STAT-3. CRC cell lines (HCT116 and HT29) were used in all the experiments. Egg CAM and HUVEC assays revealed decreased angiogenesis in ganetespib treated cell lines. Ganetespib inhibited matrigel plug vascularization and tumor growth of xenografts. Significant inhibition of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, HIF-1α and STAT-3 expression was observed in both cell lines treated ganetespib. HIF-1α overexpression resulted in the increase VEGF and STAT-3 expression and this was inhibited by ganetespib. HIF-1α knockdown inhibited VEGF and STAT-3 expression. STAT-3 knockdown inhibited VEGF but not HIF-1α expression. HSP90, STAT-3 and VEGF expression was significantly higher in CRC compared to adjacent normal tissue. Significant downregulation of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, STAT-3 and HIF-1α mRNA was observed in the post ganetespib treatment tumor samples from patients with rectal cancer. These results collectively suggest that inhibition of HSP90 is a promising antiangiogenic strategy in CRC. HSP90 angiogenic effects are mediated through HIF-1α and STAT-3.
Literatur
2.
Zurück zum Zitat Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320(2):130–137PubMedCrossRef Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320(2):130–137PubMedCrossRef
3.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef
4.
Zurück zum Zitat Joulain F, Van Cutsem E, Iqbal SU et al (eds) (2012) Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): mean overall survival (OS) estimation from a phase III trial (VELOUR). ASCO annual meeting, Chicago, IL: JCO Joulain F, Van Cutsem E, Iqbal SU et al (eds) (2012) Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): mean overall survival (OS) estimation from a phase III trial (VELOUR). ASCO annual meeting, Chicago, IL: JCO
5.
Zurück zum Zitat Grothey A, Sobrero AF, Siena S et al (eds) (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal cancer symposium; San Fransisco, CA, JCO Grothey A, Sobrero AF, Siena S et al (eds) (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Gastrointestinal cancer symposium; San Fransisco, CA, JCO
6.
Zurück zum Zitat Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271–94. Epub 2006/06/08 Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271–94. Epub 2006/06/08
7.
Zurück zum Zitat Moser C, Lang SA, Stoeltzing O (2009) Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 29(6):2031–2042. Epub 2009/06/17 Moser C, Lang SA, Stoeltzing O (2009) Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 29(6):2031–2042. Epub 2009/06/17
8.
Zurück zum Zitat Oh SH, Woo JK, Yazici YD et al (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99(12):949–961. Epub 2007/06/15 Oh SH, Woo JK, Yazici YD et al (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99(12):949–961. Epub 2007/06/15
9.
Zurück zum Zitat Prinsloo E, Kramer AH, Edkins AL et al (2012) STAT-3 interacts directly with Hsp90. IUBMB Life 64(3):266–273. Epub 2012/01/25 Prinsloo E, Kramer AH, Edkins AL et al (2012) STAT-3 interacts directly with Hsp90. IUBMB Life 64(3):266–273. Epub 2012/01/25
10.
Zurück zum Zitat Proia DA, Foley KP, Korbut T et al (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6(4):e18552. Epub 2011/05/03 Proia DA, Foley KP, Korbut T et al (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6(4):e18552. Epub 2011/05/03
11.
Zurück zum Zitat Iyer NV, Kotch LE, Agani F et al (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149–62. Epub 1998/03/07 Iyer NV, Kotch LE, Agani F et al (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149–62. Epub 1998/03/07
12.
Zurück zum Zitat Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107(1):1–3. Epub 2001/10/12 Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107(1):1–3. Epub 2001/10/12
13.
Zurück zum Zitat Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94(15):8104–8109. Epub 1997/07/22 Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94(15):8104–8109. Epub 1997/07/22
14.
Zurück zum Zitat Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) STAT-3 as an oncogene. Cell 98(3):295–303. Epub 1999/08/24 Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) STAT-3 as an oncogene. Cell 98(3):295–303. Epub 1999/08/24
15.
Zurück zum Zitat Ying W, Du Z, Sun L et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475–484. Epub 2011/12/07 Ying W, Du Z, Sun L et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475–484. Epub 2011/12/07
16.
Zurück zum Zitat Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and STAT-3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103–113. Epub 2009/02/03 Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and STAT-3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103–113. Epub 2009/02/03
17.
Zurück zum Zitat Furlan D, Sahnane N, Carnevali I et al (2007) Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol 16 Suppl 1:S25–S27. Epub 2007/11/21 Furlan D, Sahnane N, Carnevali I et al (2007) Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg Oncol 16 Suppl 1:S25–S27. Epub 2007/11/21
18.
Zurück zum Zitat Cho DC, Heath EI, Cleary JM et al (eds) (2011) A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. ASCO annual proceedings, Chicago, IL: J Clin Oncol Cho DC, Heath EI, Cleary JM et al (eds) (2011) A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. ASCO annual proceedings, Chicago, IL: J Clin Oncol
19.
Zurück zum Zitat Proia DA, Sang J, He S et al (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs Epub 2012/01/10 Proia DA, Sang J, He S et al (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs Epub 2012/01/10
20.
Zurück zum Zitat Niemisto A, Dunmire V, Yli-Harja O et al (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imag 24(4):549–553. Epub 2005/04/13 Niemisto A, Dunmire V, Yli-Harja O et al (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imag 24(4):549–553. Epub 2005/04/13
21.
Zurück zum Zitat Lang SA, Moser C, Gaumann A et al (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13(21):6459–6468. Epub 2007/11/03 Lang SA, Moser C, Gaumann A et al (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13(21):6459–6468. Epub 2007/11/03
22.
Zurück zum Zitat Xu Q, Briggs J, Park S et al (2005) Targeting STAT-3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36):5552–5560. Epub 2005/07/12 Xu Q, Briggs J, Park S et al (2005) Targeting STAT-3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36):5552–5560. Epub 2005/07/12
23.
Zurück zum Zitat Antiangiogenic drugs increase xenograft aggressiveness. Cancer Discov (2012) 2(3):OF3. Epub 2012/05/16 Antiangiogenic drugs increase xenograft aggressiveness. Cancer Discov (2012) 2(3):OF3. Epub 2012/05/16
24.
Zurück zum Zitat Conley SJ, Gheordunescu E, Kakarala P et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784–2789. Epub 2012/02/07 Conley SJ, Gheordunescu E, Kakarala P et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784–2789. Epub 2012/02/07
Metadaten
Titel
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3
verfasst von
Purnachandra Nagaraju Ganji
Wungki Park
Jing Wen
Hemchandra Mahaseth
Jerome Landry
Alton B. Farris
Field Willingham
Patrick S. Sullivan
David A. Proia
Iman El-Hariry
LaTonia Taliaferro-Smith
Roberto Diaz
Bassel F. El-Rayes
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 4/2013
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9364-7

Weitere Artikel der Ausgabe 4/2013

Angiogenesis 4/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.